Pharmacology, Toxicology and Pharmaceutical Science
Breast Cancer
100%
Placebo
38%
Chemotherapy
26%
Trastuzumab
23%
Disease Free Survival
14%
Randomized Controlled Trial
14%
Long Untranslated RNA
14%
Cyclophosphamide
13%
Docetaxel
12%
Malignant Neoplasm
12%
Overall Survival
12%
Gamma Urogastrone
11%
Metastatic Breast Cancer
10%
Epirubicin
10%
Endocrine Therapy
10%
Cohort Study
10%
Neratinib
9%
Tamoxifen
9%
Fluorouracil
8%
Methotrexate
8%
Adverse Event
7%
Recurrent Disease
6%
Deterioration
6%
Biological Marker
6%
Epidermal Growth Factor Receptor 2
6%
Neoplasm
6%
Hormone Receptor
6%
Estrogen Receptor
5%
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
5%
Progression Free Survival
5%
Anthracycline
5%
Medicine and Dentistry
Breast Cancer
99%
Metastatic Carcinoma
26%
Adjuvant Chemotherapy
16%
Trastuzumab
15%
Long Untranslated RNA
14%
Malignant Neoplasm
11%
Placebo
11%
Lymph Node
10%
Disease Free Survival
10%
Recurrent Disease
9%
microRNA
9%
Hazard Ratio
9%
Adjuvant Therapy
9%
Cyclophosphamide
8%
Overall Survival
8%
Methotrexate
8%
Fluorouracil
8%
Hormone Receptor
6%
Gamma Urogastrone
6%
Body Mass Index
6%
Hormone Therapy
5%
Estrogen Receptor
5%
Biological Marker
5%
Cohort Analysis
5%
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
5%
Reproducibility
5%
Neoadjuvant Chemotherapy
5%
Neoplasm
5%